证券记录 · 已归档季度
KYMR
Kymera Therapeutics, Inc. · Healthcare · Biotechnology
9被追踪持有人
-3Δ持有人
16.51M持有股份
$451.78M报告持仓市值
+0新建仓位
−3清仓
动量输入（同类管理人）：
持有人广度 -25.0% ·
股份流向 +5.6% ·
净新建仓位 -20.0%
— 公式
集中积累 — 持股数量上升但持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | +12 | 52.72M | $6.01B | +14 | −1 |
| Q1 2026 | 91 | -4 | 48.20M | $4.01B | +6 | −11 |
| Q4 2025 | 94 | 0 | 48.74M | $3.79B | +1 | — |
| Q3 2025 | 17 | 0 | 32.08M | $1.82B | — | −1 |
| Q2 2025 | 15 | +3 | 31.72M | $1.38B | +3 | — |
| Q1 2025 | 9 | -3 | 16.51M | $451.78M | — | −3 |
| Q4 2024 | 12 | +1 | 15.63M | $628.72M | +1 | — |
| Q3 2024 | 10 | 0 | 13.10M | $619.83M | +1 | −1 |
| Q2 2024 | 10 | — | 13.21M | $394.27M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.70M | -2.4% | $183.45M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 6.70M | -2.4% | $183.45M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 6.00M | +13.0% | $164.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | State Street Global Advisors ✦ (被动) | 1.76M | +4.3% | $48.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Geode Capital Management ✦ (被动) | 1.13M | +2.6% | $31.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Geode Capital Management ✦ (被动) | 1.13M | +2.6% | $31.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Millennium Management ✦ | 510.48K | +340.4% | $13.97M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Marshall Wace ✦ | 201.90K | +2853.9% | $5.53M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Marshall Wace ✦ | 201.90K | +2853.9% | $5.53M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 147.62K | -15.0% | $4.04M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Norges Bank ✦ (被动) | 49.70K | -45.5% | $1.36M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 2.50K | -95.7% | $68,562 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Soros Fund Management | $4.84M | 曾为 0.1% |
| D. E. Shaw & Co. | $3.32M | 曾为 0.0% |
| AQR Capital Management | $264,552 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 254 持有人, 96.17M 股份, $7.04B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据